Caris Life Sciences Announces Two Senior Vice President Appointments

Caris Life Sciences Announces Two Senior Vice President Appointments

IRVING, Texas; March 16, 2010 - Caris Life SciencesTM, Inc. - a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic technologies -  today announced the appointments of Dan Sawyers as Senior Vice President, Chief Accounting Officer, and Greg Kelly, Senior Vice President of Operations.
 
"I am quite pleased to have Dan and Greg join our management team," said Jerry A. Martino, Executive Vice President & Chief Operating Officer of Caris Life Sciences.  "Dan is well-suited to lead our accounting organization as we continue our expansion and accelerate growth, while Greg's leadership and experience will be critical to achieving world-class operational performance."

In his new position, Dan Sawyers is responsible for leading all aspects of the accounting and finance functions for Caris.  Prior to joining Caris, Dan was the Chief Accounting Officer at SOURCECORP, where he was responsible for establishing accounting policies and practices, accounting controls, and financial reporting. Prior to joining SOURCECORP, Dan was SVP and General Manager of McKesson Corporation's shared service center in Carrollton, Texas, an operation that annually processed more than $60 billion in accounts payable, accounts receivable, and contract administration transaction volume. In his role, Dan managed a staff of more than 500 employees.  Prior to these positions, Dan served as Chief Auditor at Centex Corporation and Senior Manager with Coopers & Lybrand, LLP, and spent two years in Washington D.C. as a Professional Accounting Fellow with the Office of Thrift Supervision, a division of the Treasury Department.

As Senior Vice President of Operations, Greg Kelly will manage Caris' four laboratories and drive process improvement company-wide.  Greg has more than 20 years of experience leading process improvement teams, ranging from front-line supervision to executive-level management.  He has led successful lean and operations excellence transformations in textile manufacturing, automotive, heavy machinery manufacturing, global supply chain planning, global procurement processes, and computer manufacturing and distribution.  Most recently, Greg was Senior Vice President of Operations with GENCO Supply Chain Solutions, where he led lean transformation in their 50-plus sites in North America.  Greg has also held the Director of Operations position at Dell, Inc., where he led teams that produced industry-leading results in cycle-time reduction, cost reduction, employee involvement and quality improvement.  
                                  

About Caris Life Sciences
Caris Life Sciences is a U.S.-based biosciences company specializing in the development and commercialization of the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic technologies, primarily in the fields of oncology, dermatopathology, hematopathology and gastrointestinal pathology. The company provides academic-caliber medical consults through its industry-leading team of subspecialty fellowships and expert-trained pathologists in gastrointestinal and liver pathology, dermatopathology, and hematopathology. Caris Life Sciences also offers advanced molecular analyses of patient samples through prognostic testing services and genomic and proteomic profiling to assist physicians in their treatment of cancer and other complex diseases.   Biopsies from thousands of patients are received daily for analysis by Caris from physicians.  Formed in 1996, the company is headquartered in Irving, Texas, and operates four laboratories: Irving, Texas; Phoenix, Arizona (two sites) and Newton, Massachusetts. Additional information is available at www.carislifesciences.com.

Contact
Adam McGill, Perry Street Communications, (214) 965-9955 or [email protected].

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”